Skip to content
OpenCapital
Get started

Maze Therapeutics, Inc. MAZE Q4 2024 Annual earnings

Reported March 31, 2025 · Before market open

Diluted EPS-$18.32Miss by $18.77
EPS estimate$0.45

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$2.9M
EPS estimate-$0.76

Financials

Q4 2024

Income statement

See full
EPS (diluted)$22.19—

Balance sheet

See full
Cash & equivalents$196.8M—
Total debt$26.6M—
Total equity-$311.2M—
Total assets$240.5M—

Cash flow

See full
CapEx$605.0K—

Versus estimates

Revenue

Q1 2026$20.0MBeat by $9.4M

Diluted EPS

Q1 2026-$0.45Miss by $0.02Q4 2025-$0.65Beat by $0.08Q3 2025-$0.66Beat by $0.08Q2 2025-$0.77Beat by $0.02Q1 2025-$1.15Miss by $0.39
Q4 2024-$18.32Miss by $18.77

Ask the moment Maze Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Maze Therapeutics, Inc. report Q4 2024 earnings?
Maze Therapeutics, Inc. (MAZE) reported Q4 2024 earnings on March 31, 2025 before market open.
What were Maze Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Maze Therapeutics, Inc. reported diluted EPS of $-18.32 for Q4 2024.
Did Maze Therapeutics, Inc. beat estimates in Q4 2024?
EPS missed the consensus estimate of $0.45 by $18.77.
Where can I find Maze Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-047208) directly on SEC EDGAR. The filing index links above go to sec.gov.